Bristol-Myers Squibb Company (BMY) vs Vertex Pharmaceuticals Incorporated (VRTX)
A side-by-side comparison of Bristol-Myers Squibb Company and Vertex Pharmaceuticals Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of July 28, 2026. Differences are shown without an overall score or investment verdict.
BMY
Bristol-Myers Squibb Company
$63.60HealthcareDelayed quote: Jul 28, 2026, 4:00 PM EDT
VRTX
Vertex Pharmaceuticals Incorporated
$490.39HealthcareDelayed quote: Jul 28, 2026, 4:00 PM EDT
Total return — BMY vs VRTX
growth of $100 · dividends reinvested · last 30yBMY +790.3%VRTX +3656.6%VRTX compounded faster
BMY VRTX
BMY vs VRTX: by the numbers
- •BMY is the larger company ($129.88B vs $124.46B market cap).
- •BMY trades at the lower trailing earnings multiple (17.57 vs 28.41 P/E), one valuation lens rather than an overall verdict.
- •VRTX converts more revenue to profit (35.40% vs 15.01% net margin).
- •VRTX grew revenue faster over the past five years (13.82% vs 2.52% CAGR).
- •BMY pays a dividend (4.00% yield), while VRTX has no payments in the available dividend history.
Metrics side by side
Valuation
| Metric | BMY | VRTX |
|---|---|---|
| P/E ratio | 17.57 | 28.41 |
| Forward P/E | 9.86 | 24.91 |
| P/S ratio | 2.64 | 10.02 |
| P/B ratio | 6.37 | 6.34 |
| PEG ratio | 1.87 | 3.48 |
| EV / EBITDA | 10.34 | 23.90 |
| FCF yield | 9.31% | 3.02% |
Profitability
| Metric | BMY | VRTX |
|---|---|---|
| Gross margin | 68.75% | 86.28% |
| Operating margin | 25.67% | 38.97% |
| Net margin | 15.01% | 35.40% |
| ROE | 36.25% | 22.41% |
| ROIC | 13.90% | 18.12% |
Dividends
| Metric | BMY | VRTX |
|---|---|---|
| Dividend yield | 4.00% | N/A |
| Payout ratio | 72.25% | N/A |
Growth (annualized)
| Metric | BMY | VRTX |
|---|---|---|
| Revenue CAGR (5Y) | 2.52% | 13.82% |
| EPS CAGR (5Y) | 9.38% | 8.17% |
| FCF CAGR (5Y) | -2.50% | 4.01% |
| Total return CAGR (5Y) | 2.73% | 19.51% |
Frequently asked
- Which has the lower trailing P/E, BMY or VRTX?
- BMY has the lower trailing P/E: BMY trades at 17.57 and VRTX at 28.41. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, BMY or VRTX?
- Over the past five years, VRTX grew revenue faster — BMY at a 2.52% CAGR versus VRTX at 13.82%.
- Does BMY or VRTX pay a bigger dividend?
- BMY pays a dividend (4.00% yield), while VRTX has no payments in the available dividend history.
- Is BMY or VRTX more profitable?
- VRTX runs the higher net margin — BMY at 15.01% versus VRTX at 35.40%.
- How have BMY and VRTX total returns compared?
- Over the past 10 years, BMY delivered 2.02% and VRTX delivered 17.75% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Bristol-Myers Squibb P/E ratioVertex Pharmaceuticals P/E ratioBristol-Myers Squibb dividend yieldVertex Pharmaceuticals dividend yieldBristol-Myers Squibb ROEVertex Pharmaceuticals ROEBristol-Myers Squibb operating marginVertex Pharmaceuticals operating marginBristol-Myers Squibb revenue growthVertex Pharmaceuticals revenue growthBristol-Myers Squibb free cash flowVertex Pharmaceuticals free cash flow
Bristol-Myers Squibb & Vertex Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified July 28, 2026.